Kadcyla (ado-trastuzumab emtansine) / ImmunoGen, AbbVie, Roche  >>  Phase 4
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Kadcyla (ado-trastuzumab emtansine) / Roche
NCT02658734 / 2008-005713-22: A Study of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane

Completed
4
70
RoW
Trastuzumab emtansine
Hoffmann-La Roche
HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer
12/19
12/19
ChiCTR2300072900: AN OBSERVATIONAL STUDY TO EVALUATE THE SAFETY AND EFFECTIVENESS OF TRASTUZUMAB EMTANSINE (T-DM1) AS SECOND- OR LATER-LINE THERAPY IN CHINESE PATIENTS WITH HER2-POSITIVE ADVANCED BREAST CANCER

Not yet recruiting
4
500
 
Non-intervention
Cancer Hospital, Chinese Academy of Medical Sciences; Shanghai Roche Pharmaceuticals Ltd., Shanghai Roche Pharmaceuticals Ltd.
Breast Cancer
 
 
ChiCTR2300077438: A real-world prospective observational study of T-DM1 in patients with HER2-positive advanced breast cancer

Not yet recruiting
4
50
 
Army Medical Center of PLA; Army Medical Center of PLA, Self-funded
breast cancer
 
 
ChiCTR2500107984: A Clinical study to evaluate the efficacy and safety of Herombopag in preventing thrombocytopenia caused by T-DM1 adjuvant therapy for HER-2 positive breast cancer

Not yet recruiting
4
43
 
oral herombopag
West China Hospital of Sichuan University; West China Hospital of Sichuan University, Jiangsu Hengrui Pharmaceuticals Co., Ltd
HER-2 positive breast cancer
 
 

Download Options